In late posttransplant anemia, the Correction of Anemia and Progression of Renal Insufficiency in Transplant patients (CAPRIT) study examined the 2-year effect on graft survival and quality of life of normalizing Hb levels (target level of 13-15 g/dL) versus partial Hb level correction (10.5-11.5 g/dL) by using subcutaneous epoetin beta.70 The gene discussed is GSTM1; the disease is anemia.